From the Department of Neurology (M.O., S. Suzuki), Keio University School of Medicine, Tokyo, Japan; Department of Medicine for Nephrology, Rheumatology and Endocrinology (M.-T.H.), Division of Rheumatology and Systemic Inflammatory Diseases, III, University Medical Center Hamburg-Eppendorf, Germany; Department of Medical Ethics (Y.O.), Tokai University School of Medicine; Department of Clinical Genetics (Y.O.), Tokai University Hospital, Kanagawa; Department of Neuromuscular Research (Y.S., Y.N., I.N.), National Institute of Neuroscience, and Department of Genome Medicine Development (Y.S., Y.N., I.N.), Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo; Department of Neurology (Y.N.), Nara Medical University; Department of Molecular Life Science (S. Suzuki, T.S.), Tokai University School of Medicine, Kanagawa, Japan; Department of Neuropathology (S.L.-L.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital; Department of Neuromyology (S.L.-L.), National Reference Center of Neuromuscular Disorders, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital; Department of Internal Medicine and Clinical Immunology (O.B.), Inflammatory Myopathies Reference Center, Research Center in Myology UMR974, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Universi, France; Department of Rheumatology (U.S.), and Department of Neuropathology (W.S.), Charité-Universitätsmedizin, Freie Universität Berlin, Humboldt-Universtät zu Berlin, and Berlin Institute of Health; Leibniz ScienceCampus Chronic Inflammation (W.S.), Berlin, Germany; and Department of Neurology (A.U.), Tokyo Metropolitan Neurological Hospital, Japan.
Neurology. 2024 Apr 23;102(8):e209268. doi: 10.1212/WNL.0000000000209268. Epub 2024 Mar 28.
Characteristics of myositis with anti-Ku antibodies are poorly understood. The purpose of this study was to elucidate the pathologic features of myositis associated with anti-Ku antibodies, compared with immune-mediated necrotizing myopathy (IMNM) with anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies, in muscle biopsy-oriented registration cohorts in Japan and Germany.
We performed a retrospective pathology review of patients with anti-Ku myositis samples diagnosed in the Japanese and German cohorts. We evaluated histologic features and performed HLA phenotyping.
Fifty biopsied muscle samples in the Japanese cohort and 10 in the German cohort were obtained. After exclusion of myositis-specific autoantibodies or other autoimmune connective tissue diseases, 26 samples (43%) of anti-Ku antibody-positive myositis were analyzed. All the samples shared some common features with IMNM, whereas they showed expression of MHC class II and clusters of perivascular inflammatory cells more frequently than the anti-SRP/HMGCR IMNM samples (71% vs 7%/16%; < 0.005/<0.005; 64% vs 0%/0%; < 0.005/<0.005). Anti-Ku myositis biopsies could be divided into 2 subgroups based on the extent of necrosis and regeneration. The group with more abundant necrosis and regeneration showed a higher frequency of MHC class II expression and perivascular inflammatory cell clusters. HLA phenotyping in the 44 available patients showed possible associations of HLA-DRB103:01, HLA-DRB111:01, and HLA-DQB103:01 ( = 0.0045, 0.019, and 0.027; odds ratio [OR] 50.2, 4.6, and 2.8; 95% CI 2.6-2942.1, 1.1-14.5, and 1.0-7.0) in the group with less conspicuous necrosis and regeneration. On the contrary, in the group of more abundant necrosis and regeneration, the allele frequencies of HLA-A24:02, HLA-B52:01, HLA-C12:02, and HLA-DRB1*15:02 were lower than those of healthy controls ( = 0.0036, 0.027, 0.016, and 0.026; OR = 0.27, 0, 0, and 0; 95% CI 0.1-0.7, 0-0.8, 0-0.8, and 0-0.8). However, these HLA associations did not remain significant after statistical correction for multiple testing.
While anti-Ku myositis shows necrotizing myopathy features, they can be distinguished from anti-SRP/HMGCR IMNM by their MHC class II expression and clusters of perivascular inflammatory cells. The HLA analyses suggest that anti-Ku myositis may have different subsets associated with myopathologic subgroups.
抗 Ku 抗体肌炎的特征尚未完全明确。本研究旨在阐明与抗信号识别颗粒(SRP)和抗 3-羟基-3-甲基戊二酰辅酶 A 还原酶(HMGCR)抗体相关的免疫介导性坏死性肌病(IMNM)相比,抗 Ku 抗体肌炎的病理特征,这些特征是在日本和德国的肌肉活检导向注册队列中发现的。
我们对日本和德国队列中诊断为抗 Ku 肌炎的患者的肌肉活检样本进行了回顾性病理检查。我们评估了组织学特征并进行了 HLA 表型分析。
在日本队列中获得了 50 个活检肌肉样本,在德国队列中获得了 10 个。在排除肌炎特异性自身抗体或其他自身免疫性结缔组织疾病后,分析了 26 个(43%)抗 Ku 抗体阳性肌炎样本。所有样本均与 IMNM 具有一些共同特征,但与抗 SRP/HMGCR IMNM 样本相比,它们表现出 MHC Ⅱ类表达和血管周围炎性细胞簇更为频繁(71%与 7%/0%;<0.005/<0.005;64%与 0%/0%;<0.005/<0.005)。根据坏死和再生的程度,抗 Ku 肌炎活检可分为 2 个亚组。坏死和再生更为丰富的组显示出更高频率的 MHC Ⅱ类表达和血管周围炎性细胞簇。在 44 名可进行 HLA 表型分析的患者中,HLA-DRB103:01、HLA-DRB111:01 和 HLA-DQB103:01 与较少明显的坏死和再生组相关(=0.0045、0.019 和 0.027;比值比[OR] 50.2、4.6 和 2.8;95%置信区间[CI] 2.6-2942.1、1.1-14.5 和 1.0-7.0)。相反,在坏死和再生更为丰富的组中,HLA-A24:02、HLA-B52:01、HLA-C12:02 和 HLA-DRB1*15:02 的等位基因频率低于健康对照组(=0.0036、0.027、0.016 和 0.026;OR 0.27、0、0 和 0;95%CI 0.1-0.7、0-0.8、0-0.8 和 0-0.8)。然而,在进行多次检验的统计校正后,这些 HLA 关联并不显著。
尽管抗 Ku 肌炎表现出坏死性肌病特征,但与抗 SRP/HMGCR IMNM 相比,它们可以通过 MHC Ⅱ类表达和血管周围炎性细胞簇来区分。HLA 分析表明,抗 Ku 肌炎可能与不同的肌病亚群相关。